Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality
among highly immunocompromised patients. Authoritative consensus criteria to diagnose …

Randomized clinical trials for patients with invasive fungal infections (IFIs) are often limited
or precluded, necessitating alternate sources of information. The Prospective Antifungal …

Invasive fungal infections are on the rise and during recent years understanding the
epidemiology of fungal infections improved. Over 1 billion people are affected and 25 million …

Background. Invasive fungal diseases are important causes of morbidity and mortality.
Clarity and uniformity in defining these infections are important factors in improving the …

Abstract Background Invasive fungal diseases (IFDs) remain important causes of morbidity
and mortality. The consensus definitions of the Infectious Diseases Group of the European …

Breakthrough invasive fungal infections (IFI s) have emerged as a significant problem in
patients receiving systemic antifungals; however, consensus criteria for defining …

Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections;
however, it is associated with significant toxicities that limit its use. Other systemic antifungal …

Invasive mycoses present a global challenge with expansion into new hosts, emergence of
new pathogens, and development of multidrug resistance. In parallel, new antifungal agents …

Outcomes for invasive fungal infections have greatly improved in the past decade, and
several new antifungal drugs have been or will be licensed in the next few years. Early …

Invasive mycoses pose a major diagnostic and therapeutic challenge. Advances in
antifungal agents and diagnostic methods offer the potential for improved outcomes in …